(Total Views: 703)
Posted On: 10/06/2023 3:59:03 AM
Post# of 154851
GSK was using monophosphoryl lipid A (MPL) to boost vaccine response. It does this by activating Toll Like Receptor 4 (TLR-4) to increase dendritic cells and monocytes. TLR-4 also causes an inflammatory response. Leronlimab also increases dendritic cells and monocytes in a non-TLR-4 and non-inflammatory manner.
Quite awhile back I posited that leronlimab may be able to boost vaccine efficacy. It may have been in relation to Covid-19 vaccines. There may be another avenue to what GSK's MPL can do if anybody would pay attention.
Quote:
Percent of total immune cells in long-term Leronlimab treatment in humans.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970399/
Quite awhile back I posited that leronlimab may be able to boost vaccine efficacy. It may have been in relation to Covid-19 vaccines. There may be another avenue to what GSK's MPL can do if anybody would pay attention.
(13)
(0)
